Zhijie Wang

Dr. Zhijie Wang


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
JDJianchun Duan
Jianchun Duan
LCLonggang Cui
Longgang Cui
XZXiaochen Zhao
Xiaochen Zhao
HBHua Bai
Hua Bai
SCShangli Cai
Shangli Cai
JWjie wang
jie wang
Immunotherapy is one of the most important breakthroughs in cancer treatment, especially immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) and PD ligand 1 (PD-L1), which significantly prolonged overall survival (OS) and possessed superior safety profile in patients with cancer compared with standard therapies across a wide range of tumor types.1,2 With the increasing studies in immunotherapy, differences between the clinical performance of anti–PD-1 and anti–PD-L1 started to be reported. For example, recent findings from the KEYNOTE-426 study demonstrated significant OS improvement with the combination of anti–PD-1 (pembrolizumab) plus axitinib vs sunitinib in previously untreated patients with advanced renal cell carcinoma (RCC)3; however, anti–PD-L1 (avelumab) plus axitinib failed to demonstrate OS superiority over sunitinib in the same settings.4 In addition, anti–PD-1 (pembrolizumab) plus carboplatin and nab-paclitaxel has been approved by the US Food and Drug Administration for first-line treatment of metastatic, squamous non–small cell lung cancer (NSCLC) based on the positive results from KEYNOTE-407,5 while anti–PD-L1 (atezolizumab) plus carboplatin and nab-paclitaxel failed to show an OS benefit compared with chemotherapy in squamous NSCLC in IMpower131.6,7 Such disparities have attracted widespread attention by clinicians, and there is a need to better understand the similarities and differences between anti–PD-1 and anti–PD-L1 for the ultimate benefit of patients with cancer.

1 January 2020 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
JHJiefei Han
Jiefei Han
JDJianchun Duan
Jianchun Duan
HBHua Bai
Hua Bai
YWYuqi Wang
Yuqi Wang
RWRui Wan
Rui Wan
JWjie wang
jie wang
T-cell receptor (TCR)–based biomarkers might predict patient response to immune checkpoint blockade (ICB) but need further exploration and validation for that use. We sequenced complementarity-determining region 3 of TCRβ chains isolated from PD-1+ CD8+ T cells to investigate its value for predicting the response to anti–programmed cell death 1 (PD-1)/PD-ligand 1 (PD-L1) therapy in patients with non–small cell lung cancer (NSCLC). Two independent patient cohorts (cohort A, n = 25; cohort B, n = 15) were used as discovery and validation sets, respectively. Pre- and post-ICB peripheral blood samples were collected. In cohort A, patients with high PD-1+ CD8+ TCR diversity before ICB treatment showed better response to ICB and progression-free survival (PFS) compared with patients with low diversity [6.4 months vs. 2.5 months, HR, 0.39; 95% confidence interval (CI), 0.17–0.94; P = 0.021]. The results were validated in cohort B. Pre-ICB PD-1+ CD8+ TCR diversity achieved an optimal Youden's index of 0.81 (sensitivity = 0.87 and specificity = 0.94) for differentiating the ICB response in the merged dataset (cohort A plus cohort B). Patients with increased PD-1+ CD8+ TCR clonality after ICB treatment had longer PFS (7.3 months vs. 2.6 months, HR, 0.26; 95% CI, 0.08–0.86; P = 0.002) than those with decreased clonality. Thus, TCR diversity and clonality in peripheral blood PD-1+ CD8+ T cells may serve as noninvasive predictors of patient response to ICB and survival outcomes in NSCLC.

15 February 2010 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SWShuhang Wang
Shuhang Wang
TATongtong An
Tongtong An
JWJie Wang
Jie Wang
JZJUN ZHAO
JUN ZHAO
ZWZhijie Wang
Zhijie Wang
MWMeina Wu
Meina Wu
Purpose: Non–small cell lung cancer (NSCLC) with KRAS mutation may be resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). This study aims to evaluate a plasma-based KRAS mutation analysis and the clinical significance of plasma KRAS mutation as a predictive marker for tumor resistance to EGFR-TKIs in patients with NSCLC. Experimental Design: DNA extracted from plasma and matched tumor tissues were obtained from 273 patients with advanced stage NSCLC. Patients were followed up prospectively for treatment outcomes. KRAS mutations in codon 12 and 13 were detected using PCR-restriction fragment length polymorphism. Mutations in plasma and matched tumors were compared. Associations between KRAS mutation status and patients' clinical outcomes were analyzed. Results: KRAS mutation was found in 35 (12.8%) plasma samples and 30 (11.0%) matched tumor tissues. The consistency of KRAS mutations between plasma and tumors is 76.7% (23 of 30; κ = 0.668; P < 0.001). Among 120 patients who received EGFR-TKI treatment, the response rate was only 5.3% (1 of 19) for patients with plasma KRAS mutation compared with 29.7% for patients with no KRAS mutation in plasma DNA (P = 0.024). The median progression-free survival time of patients with plasma KRAS mutation was 2.5 months compared with 8.8 months for patients with wild-type KRAS (P < 0.001). Conclusions: KRAS mutation in plasma DNA correlates with the mutation status in the matched tumor tissues of patients with NSCLC. Plasma KRAS mutation status is associated with a poor tumor response to EGFR-TKIs in NSCLC patients and may be used as a predictive marker in selecting patients for such treatment. Clin Cancer Res; 16(4); 1324–30

6 January 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
YWYu Wang
Yu Wang
TZTao Zhang
Tao Zhang
JWJianyang Wang
Jianyang Wang
ZZZongmei Zhou
Zongmei Zhou
WLWenyang Liu
Wenyang Liu
NBNan Bi
Nan Bi

10 March 2022 in Molecular Diagnosis & Therapy
Verified
Journal Article
Open access
PDF file
YDYiting Dong
Yiting Dong
JXJiachen Xu
Jiachen Xu
BSBoyang Sun
Boyang Sun
JWjie wang
jie wang
ZWZhijie Wang
Zhijie Wang
Introduction Numerous therapeutic agents specifically targeting the mesenchymal-epithelial transition (MET) oncogene are being developed. Objective The aim of the current review was to systematically identify and analyze clinical trials that have evaluated MET inhibitors in various cancer types and to provide an overview of their clinical outcomes. Methods An electronic literature search was carried out in the PubMed and Embase databases to identify published clinical trials related to MET inhibitors. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement was followed for the systematic appraisal of the literature. Data related to clinical outcomes, including progression-free survival, overall survival, objective response rate, and overall tumor response, were extracted. Results In total, 49 publications were included. Among these, 51.02% were phase II studies, 14.28% were randomized controlled trials, three were phase III studies, two were prospective observational studies, and the remainder were either phase I or Ib studies. The majority (44.89%) of articles reported the clinical outcomes of MET inhibitors, including small molecules, monoclonal antibodies, and other agents, in patients with non-small-cell lung cancer (NSCLC) harboring MET alterations. MET amplification, overexpression, and MET exon 14 skipping mutations were the major MET alteration types reported across the included studies. Clinical responses/outcomes varied considerably. Conclusion This systematic literature review provides an overview of the literature available in Embase and PubMed regarding MET-targeted therapies. MET-selective tyrosine kinase inhibitors (TKIs) (capmatinib, tepotinib, and savolitinib) may become a new standard of care in NSCLC, specifically with MET exon 14 skipping mutations. A combination of MET TKIs with epidermal growth factor receptor (EGFR) TKIs (osimertinib + savolitinib, tepotinib + gefitinib) may be a potential solution for MET-driven EGFR TKI resistance. Further, MET alteration (MET amplification/overexpression) may be an actionable target in gastric cancer and papillary renal cell carcinoma.

27 March 2024 in EBioMedicine
Verified
Journal Article
Open access
JXJiachen Xu
Jiachen Xu
YZYundi Zhang
Yundi Zhang
MLMan Li
Man Li
ZSZhuo Shao
Zhuo Shao
YDYiting Dong
Yiting Dong
ZWZhijie Wang
Zhijie Wang
The high heterogeneity of tumour and the complexity of tumour microenvironment (TME) greatly impacted the tumour development and the prognosis of cancer in the era of immunotherapy. In this study, we aimed to portray the single cell-characterised landscape of lung adenocarcinoma (LUAD), and develop an integrated signature incorporating both tumour heterogeneity and TME for prognosis stratification. Single-cell tagged reverse transcription sequencing (STRT-seq) was performed on tumour tissues and matched normal tissues from 14 patients with LUAD for immune landscape depiction and candidate key genes selection for signature construction. Kaplan-Meier survival analyses and in-vitro cell experiments were conducted to confirm the gene functions. The transcriptomic profile of 1949 patients from 11 independent cohorts including nine public datasets and two in-house cohorts were obtained for validation. We selected 11 key genes closely related to cell-to-cell interaction, tumour development, T cell phenotype transformation, and Ma/Mo cell distribution, including HLA-DPB1, FAM83A, ITGB4, OAS1, FHL2, S100P, FSCN1, SFTPD, SPP1, DBH-AS1, CST3, and established an integrated 11-gene signature, stratifying patients to High-Score or Low-Score group for better or worse prognosis. Moreover, the prognostically-predictive potency of the signature was validated by 11 independent cohorts, and the immunotherapeutic predictive potency was also validated by our in-house cohort treated by immunotherapy. Additionally, the in-vitro cell experiments and drug sensitivity prediction further confirmed the gene function and generalizability of this signature across the entire RNA profile spectrum. This single cell-characterised 11-gene signature might offer insights for prognosis stratification and potential guidance for treatment selection. Support for the study was provided by National key research and development project (2022YFC2505004, 2022YFC2505000 to Z.W. and J.W.), Beijing Natural Science Foundation (7242114 to J.X.), National Natural Science Foundation of China of China (82102886 to J.X., 81871889 and 82072586 to Z.W.), Beijing Nova Program (20220484119 to J.X.), NSFC general program (82272796 to J.W.), NSFC special program (82241229 to J.W.), CAMS Innovation Fund for Medical Sciences (2021-1-I2M-012, 2022-I2M-1-009 to Z.W. and J.W.), Beijing Natural Science Foundation (7212084 to Z.W.), CAMS Key lab of translational research on lung cancer (2018PT31035 to J.W.), Aiyou Foundation (KY201701 to J.W.). Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences (CICAMS-MOCP2022003 to J.X.).